{"id":"https://openalex.org/W1987705191","doi":"https://doi.org/10.1097/00001813-200207000-00010","title":"Non-linear pharmacokinetics of irinotecan in mice","display_name":"Non-linear pharmacokinetics of irinotecan in mice","alternate_titles":[],"publication_year":2002,"publication_date":"2002-07-01","ids":{"openalex":"https://openalex.org/W1987705191","doi":"https://doi.org/10.1097/00001813-200207000-00010","mag":"1987705191","pmid":"https://pubmed.ncbi.nlm.nih.gov/12172509"},"language":"en","primary_location":{"id":"doi:10.1097/00001813-200207000-00010","doi":"https://doi.org/10.1097/00001813-200207000-00010","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-200207000-00010","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1987705191"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036490187","display_name":"Elisabeth Rouits","orcid":"https://orcid.org/0000-0002-5993-8824","observed_orcids":["https://orcid.org/0000-0002-5993-8824"]},"institutions":[{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Elisabeth Rouits","raw_affiliation_strings":["Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France","institution_ids":["https://openalex.org/I4210128666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040373927","display_name":"Sylvie Mireille Guichard","orcid":"https://orcid.org/0000-0003-1143-2805","observed_orcids":["https://orcid.org/0000-0003-1143-2805"]},"institutions":[{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Sylvie Guichard","raw_affiliation_strings":["Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France","institution_ids":["https://openalex.org/I4210128666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041701219","display_name":"Pierre Canal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Pierre Canal","raw_affiliation_strings":["Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France","institution_ids":["https://openalex.org/I4210128666"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002862341","display_name":"\u00c9tienne Chatelut","orcid":"https://orcid.org/0000-0002-7740-9096","observed_orcids":["https://orcid.org/0000-0002-7740-9096"]},"institutions":[{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Etienne Chatelut","raw_affiliation_strings":["Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Claudius-Regaud, EA 3035, 20 rue du Pont-St-Pierre, 31052 Toulouse, France","institution_ids":["https://openalex.org/I4210128666"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5040373927"],"corresponding_institution_ids":["https://openalex.org/I4210128666"],"apc_list":null,"apc_paid":null,"fwci":0.0946,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.34353104,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"13","issue":"6","first_page":"631","last_page":"635"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9721999764442444,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9721999764442444,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.020099999383091927,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/sn-38","display_name":"SN-38","score":0.9390000104904175},{"id":"https://openalex.org/keywords/nonlinear-pharmacokinetics","display_name":"nonlinear pharmacokinetics","score":0.9380000233650208},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.8460000157356262},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.47699999809265137},{"id":"https://openalex.org/keywords/saturable-metabolism","display_name":"saturable metabolism","score":0.6129999756813049},{"id":"https://openalex.org/keywords/population-pharmacokinetic-model","display_name":"population pharmacokinetic model","score":0.6769999861717224},{"id":"https://openalex.org/keywords/mice","display_name":"mice","score":0.5910000205039978},{"id":"https://openalex.org/keywords/species-differences","display_name":"species differences","score":0.44699999690055847},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.8240000009536743}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.9281476140022278},{"id":"https://openalex.org/C2776239304","wikidata":"https://www.wikidata.org/wiki/Q6954915","display_name":"NONMEM","level":3,"score":0.8147920370101929},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.793739914894104},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7486478090286255},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.5972599387168884},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5286034941673279},{"id":"https://openalex.org/C2779682216","wikidata":"https://www.wikidata.org/wiki/Q419964","display_name":"Camptothecin","level":2,"score":0.5126163363456726},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.48467138409614563},{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.43507954478263855},{"id":"https://openalex.org/C2780508388","wikidata":"https://www.wikidata.org/wiki/Q1750127","display_name":"SN-38","level":5,"score":0.4214818477630615},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.32969072461128235},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.29347944259643555},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.19481098651885986},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1916784942150116},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0535338819026947},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002265","descriptor_name":"Carboxylic Ester Hydrolases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017711","descriptor_name":"Nonlinear Dynamics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D043182","descriptor_name":"Carboxylesterase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00001813-200207000-00010","doi":"https://doi.org/10.1097/00001813-200207000-00010","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-200207000-00010","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:12172509","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12172509","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8048999905586243,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W142918889","https://openalex.org/W1480716635","https://openalex.org/W1794341310","https://openalex.org/W1894737231","https://openalex.org/W1944765939","https://openalex.org/W1982154712","https://openalex.org/W1986896123","https://openalex.org/W2016722642","https://openalex.org/W2019867999","https://openalex.org/W2024980393","https://openalex.org/W2153544919","https://openalex.org/W2169186295","https://openalex.org/W2311628233"],"related_works":["https://openalex.org/W2908229852","https://openalex.org/W2311628233","https://openalex.org/W2145619143","https://openalex.org/W3173651342","https://openalex.org/W1777256341","https://openalex.org/W2069494336","https://openalex.org/W3003305233","https://openalex.org/W1585209741","https://openalex.org/W2393326445","https://openalex.org/W2118644245"],"abstract_inverted_index":{"Irinotecan":[0],"(CPT-11)":[1],"is":[2,20,159],"a":[3,54,112],"topoisomerase":[4],"I":[5],"inhibitor":[6],"used":[7],"in":[8,51,162],"the":[9,24,31,36,42,45,59,115,122,126,131,138,141,144,149,155],"treatment":[10],"of":[11,30,38,44,47,49,75,90,107,114,130,140,146,157,165],"metastatic":[12],"colorectal":[13],"cancer.":[14],"Its":[15],"conversion":[16,106],"by":[17,97,177],"carboxyl":[18],"esterases":[19],"necessary":[21],"to":[22,34,109,135,172],"form":[23],"active":[25],"metabolite":[26],"SN-38.":[27],"The":[28],"aims":[29],"study":[32],"were":[33,67,95],"evaluate":[35,136],"linearity":[37],"CPT-11":[39,50,92,108,158],"pharmacokinetics":[40,156],"and":[41,72,86,93,118,143,168],"influence":[43],"schedule":[46,145],"administration":[48,76,147],"mice,":[52],"using":[53,69],"population":[55],"pharmacokinetic":[56,100,150,167],"approach":[57],"with":[58],"NON-linear":[60],"Mixed":[61],"Effects":[62],"Model":[63],"(NONMEM)":[64],"program.":[65],"Mice":[66],"treated":[68],"two":[70,73],"doses":[71],"schedules":[74],"[10":[77],"mg/kg/day":[78,82],"(dailyx5)x2":[79],"or":[80],"50":[81],"on":[83,103,148],"days":[84],"1":[85],"12].":[87],"Plasma":[88],"concentrations":[89],"both":[91,104,137,166],"SN-38":[94,110],"determined":[96],"HPLC.":[98],"A":[99],"model":[101,132],"based":[102],"immediate":[105],"for":[111,121,180],"fraction":[113,124],"administered":[116],"dose":[117,142],"saturable":[119],"process":[120],"remaining":[123],"fitted":[125],"data":[127],"well.":[128],"Refinements":[129],"allowed":[133],"us":[134],"impacts":[139],"parameters.":[151],"We":[152],"conclude":[153],"that":[154],"not":[160],"linear":[161],"mice.":[163],"Extrapolation":[164],"pharmacodynamic":[169],"preclinical":[170],"results":[171],"humans":[173],"may":[174],"be":[175],"limited":[176],"species":[178],"particularities":[179],"this":[181],"drug.":[182]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1987705191","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}
